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Results Independently from cells differentiation status, 
testosterone, with an insulin-like effect, induced Glut4-
mRNA expression, GLUT4 protein translocation to the 
cytoplasmic membrane, while no effect was observed on 
GLUT4 protein expression levels. Furthermore, testos-
terone treatment modulated the insulin-dependent signal 
transduction pathways inducing a rapid and persistent acti-
vation of AKT, ERK and mTOR, and a transient inhibition 
of GSK3β. T-related effects were shown to be androgen 
receptor dependent.
Conclusion All together our data indicate that testosterone 
through the activation of non-genomic pathways, partici-
pates in skeletal muscle glucose metabolism by inducing 
insulin-related effects.
Keywords Testosterone · Metabolism · Insulin · Human 
skeletal muscle cells
Introduction
Endogenous androgens [e.g., testosterone (T), dihy-
drotestosterone (DHT)] influence both reproductive and 
non-reproductive functions in humans through the regula-
tion of early non-genomic and late-genomic biochemical 
pathways [1–3]. Whether androgens-mediated long-term 
effects have been largely characterized, few data exist on 
short-term effects. We know that acute physical exercise 
induces a rapid increase in the human serum endogenous 
levels of several circulating factors such as T [4–6], but the 
related short-term effects on T-targeted cells, such as skel-
etal muscle cells, have been not yet characterized. Skeletal 
muscle is the major tissue involved in glucose metabolism 
accounting for ≈85% of whole-body insulin-stimulated 
glucose uptake [7]. Data from animal models show that T 
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influences glucose through non-genomic insulin-like mech-
anisms in adipocytes, cardiomyocytes and myoblast cells 
[8–11]. T insulin-like effects on human skeletal muscle 
cells has been not yet fully investigated. Considering the 
possible role of T in promoting skeletal muscle cells home-
ostasis and recovery, particularly during prolonged physical 
exercise and/or after ending exercise [12], we have hypoth-
esized that the observed acute rapid T increases induced by 
physical activity could modulate insulin-related early non-
genomic pathways, thus impacting on the glucose metabo-
lism and promoting muscle cells metabolic homeostasis 
and/or recovery. We have investigated the short-term effects 
of T on human muscle metabolic functions in vitro using 
human cultures of fetal skeletal muscle cells (Hfsmc) [13] 
treated with T (100 nM) or insulin (I) (100 nM). The gene 
expression of glucose transporter type 4, 3 and 1 (Glut4, 
Glut3 and Glut1, respectively), the translocation of GLUT4 
and the activation of I-responsive protein kinase B (PKB/
AKT), extracellular-signal-regulated kinases (ERK1/2), 
mammalian target of rapamycin (mTOR), and glycogen 
synthase kinase 3β (GSK3β) were investigated.
Materials and methods
Chemicals
DMEM/Ham’s F-12 medium (1:1) with and without phe-
nol red, phosphate buffered saline (PBS)  Ca2+/Mg2+-
free, bovine serum albumin (BSA) fraction V, glutamine, 
antibiotics, collagenase type IV, NaOH, Bradford reagent, 
4′,6-Diamidino-2-phenylindole (DAPI) and all reagents 
for western blot were from Sigma-Aldrich (St. Louis, 
MO, USA). Fetal calf serum was from HyClone (Logan, 
UT). Testosterone (T6147) and bicalutamide (B9061) 
were purchased from Sigma-Aldrich (St. Louis, MO, 
USA). 2-Mercaptoethanol was purchased from Life Tech-
nologies, Inc. Laboratories (Grand Island, NY). Anti-
bodies (Abs) for western blot and immunocytochemical 
analysis: rabbit polyclonal primary anti-phospho Ser2448 
mTOR (p-mTOR), mTOR, Ser-473 AKT (p-AKT), AKT, 
Thr-44, and Tyr-42 ERK (p-ERK1/2), ERK2, Ser21/9 
GSK3β, GSK3β, mouse monoclonal primary anti-β actin 
were from Santa Cruz (Santa Cruz, CA, USA); rabbit 
polyclonal primary anti-GLUT4. Cy3-labeled second-
ary antibody were from Jackson Laboratory (Maine, 
USA), peroxidase secondary Abs, all reagents for SDS-
PAGE were from Millipore (Billerica, MA, USA). For 
RNA extraction TRIzol RNA Isolation reagent was pur-
chased by Ambion™; for reverse transcription 10 mM 
dNTP Mix, Random Primers, RNaseOUT™ Ribonu-
clease inhibitor and  SuperScript® III Reverse were pur-
chased from Invitrogen.  SYBR® Green PCR Master 
Mix for qPCR was purchased from Life Technologies™ 
(Applied  Biosystems®). Primers were from invitrogen. 
Primers for Glut1: Fw CAAGACTGGAGTCATCAT-
CAATGC, Rev: AGGATGCTCTCCCCAAGC; for Glut3: 
Fw CTCCTTTTCCGTCGGACTCT; for Glut4: Fw CAC-
CCTCACCACCCTCTG, Rev CTTTTCCTTCCAAGC-
CACTG; for β actin: Fw CTGAACCCCAAGGCCAAC, 
Rev AGCCTGGATAGCAACGTACA. Plasticware for 
cell cultures and disposable filtration units for growth 
media preparation were purchased from Corning (Milan, 
Italy).
Cell cultures
Hfsmc were obtained as previously described [13, 14]. 
Cells were isolated from 11 fetal skeletal male muscles 
(four upper and seven lower limbs) obtained after voluntary 
abortion (10–12 weeks of gestation to set up fetal tissue 
sample collection previously used [15]). Legal abortions 
were performed in authorized hospitals and written consent 
was given by the patients for their human fetal tissue to be 
stored and used for research. The use of human fetal tissue 
for research purposes was approved by the Committee for 
investigation in humans of the Azienda Ospedaliero-Uni-
versitaria Careggi, Florence, Italy (protocol no 6783-04). 
All fetal tissue samples have been handled in the same way 
and maintained in ice-cold PBS until processed for culture 
preparation as described elsewhere [13, 14]. Confluent cell 
cultures were split into a 1:2–1:4 ratio using EDTA-trypsin 
solution (0.2–0.5%), and used from 5th to 12th passage 
(5p–12p).
RNA extraction, reverse transcription and real‑time 
quantitative PCR
For mRNA analysis 35 × 103 Hfsmc were seeded and 
maintained for 24 h or 5 days in serum-free medium to 
differentiate in myotubes. Cells before and after differen-
tiation were stimulated with T (100 nM) and I (100 nM) 
for 24 h in serum-free medium containing 0.1% BSA. 
Cells in serum-free medium with 0.1% BSA and vehicle 
were used as control. Total RNA and reverse-transcribed-
RNA were prepared as described elsewhere [16]. Single-
stranded cDNA was obtained by reverse transcription of 
1 µg of total RNA. RT-qPCR was performed using 7500 
Real Time System (Applied  Biosystems®) with SYBR-
green fluorophore; 40 ng of cDNA were used as template 
and cycling parameters were 95 °C for 10 min, followed 
by 40 cycles of 15 s at 95 °C, 1 min at 60 °C, 30 s at 
95 °C, 15 s at 60 °C. Fluorescence intensities were ana-
lyzed using the manufacturer’s software (7500 Software 
v2.05) and relative amounts were obtained using the 
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 2−∆∆Ct method and normalized for the ß-actin. Data are 
expressed as fold increase vs. control taken as 1.
Protein expression analysis
For protein analysis, Hfsmc, seeded and maintained in the 
same conditions as previously reported [17], were stimu-
lated for 15 and 30 min, 2, 6 and 12 h in presence or absence 
of T (100 nM) in serum-free medium containing 0.1% 
BSA; cells were treated for 15 min with I (100 nM) for 
comparison. Androgen receptor antagonism was obtained 
by pre-treating Hfsmc with 100 nM of bicalutamide for 1 h 
before T treatments. Cells in serum-free medium with 0.1% 
BSA and vehicle were used as control. Protein concentra-
tion measurement was performed with Bradford Reagent. 
Protein aliquots (20 μg) were processed, loaded onto 10% 
SDS-PAGE and transferred on PVDF membranes, accord-
ing to the procedure previously described [18, 19]. There-
after, membranes were incubated with primary Abs appro-
priately diluted in Tween Tris-buffered saline (TTBS) (for 
anti-p-AKT, anti-AKT, anti-p-mTOR, anti-mTOR, anti-p-
ERK1/2, anti ERK2, anti-p-GSK3β, anti-GSK3β 1:1000; 
for anti-β actin 1:5000), followed by peroxidase-conju-
gated secondary IgG (1:10,000). Proteins were revealed by 
the enhanced chemiluminescence system (ECL plus; Milli-
pore). Image acquisition was performed with Image Quant 
Las 4000 software (GE Healthcare) and densitometric anal-
ysis with Quantity  One® software (Bio-Rad laboratories 
Inc.). Western blot analysis was performed in three/four 
independent experiments with different cell preparations.
Immunofluorescence microscopy
104 cells were seeded onto glass coverslips in growth 
medium and maintained for 24 h or 5 days in serum-free 
medium for differentiation. For GLUT4 localization cells 
were stimulated for 30 min with T 100 nM and I 100 nM 
in serum-free medium containing 0.1% BSA. Androgen 
receptor antagonism was obtained by pre-treating Hfsmc 
with 100 nM of bicalutamide for 1 h before T treatments. 
Cells in serum-free medium with 0.1% BSA and vehicle 
were used as controls. For method specificity, slides lack-
ing the primary Abs were processed. To evaluate GLUT4 
translocation cells were fixed with 4% PFA to leave intact 
plasmalemma and incubated with blocking buffer contain-
ing 1% BSA for 30 min at room temperature. Ab GLUT4 
(1:100) was incubated overnight, followed by Cy3 conju-
gated secondary Ab (1.400). DAPI nucleic acid stain was 
used to dye nuclei (1:10,000). Images were acquired at 
60× magnification and slides were examined with Zeiss 
Z1 microscope and Leica TCS SP2 (Leica, Milano, Italy). 
For quantification: the percentage of GLUT4 positive 
cells was calculated by counting the number of stained 
cells over the total in at least 10 separate fields per slide. 
Experiments were performed three times with different 
cell preparations.
Statistical analysis
The statistical analysis was performed using GraphPad 
Prism 5 software (GraphPad Software, Inc., La Jolla, CA, 
USA). T test was applied and P value <0.05 was con-
sidered significant and corrected for comparison using 
Bonferroni’s post hoc test. Data were expressed as the 
mean ± standard error (SEM).
Results
Testosterone‑induced Glut4 mRNA expression 
in undifferentiated and differentiated Hfsmc
mRNA specific for glucose transporter subtypes Glut4, 
Glut3 and Glut1 was analyzed by qPCR analysis in undif-
ferentiated or differentiated Hfsmc cells, treated for 24 h 
with T or I, as shown in Fig. 1. T significantly (P < 0.01) 
increased Glut4 mRNA expression in undifferentiated 
(3.21 ± 0.78 fold of induction vs. c) or differentiated 
(4.58 ± 0.82 fold of induction vs. c) Hfsmc cells vs. 
basal expression (control) taken as 1; no changes were 
observed after I or T in Glut1 and Glut3 mRNA expres-
sion vs. control cells. Furthermore, T seems to retain a 
stronger efficiency in inducing mRNA Glut4 expression 
vs. I treatment (2.12 ± 0.11-fold of induction vs. control) 
in Hfsmc differentiated cells.
Testosterone‑induced GLUT4 membrane recruitment 
in undifferentiated and differentiated Hfsmc
The effect of T on GLUT4 localization was investigated. 
Immunofluorescence for GLUT4 performed onto non-
permeabilized undifferentiated Hfsmc treated with T for 
30 min revealed a stronger positive signal vs. control 
cells, similarly to I, used as positive control (Fig. 2a, 
upper panels, undifferentiated).
Similar results were observed in non-permeabilized 
differentiated Hfsmc (differentiated), where positive spe-
cific staining for GLUT4 was stronger after T or I vs. 
control (Fig. 2a, upper panels, differentiated). Middle and 
lower panels of Fig. 2a depict, respectively, nuclei DAPI 
labeling and GLUT4/DAPI fluorescence merging for 
each conditions.
Percentage analysis of GLUT4 positive cells shows 
that T-mediated GLUT4 translocation was induced by 
99.3% ± 3.1 and 83.4 ± 9.9% in undifferentiated and in 
differentiated cells, respectively; P < 0.01 vs. control. I 
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induced GLUT4 membrane recruitment in virtually 100% 
of undifferentiated and differentiated cells (Fig. 2b).
Testosterone rapid effect on insulin‑related pathway 
activation
The effects of T onto I-related signal transduction path-
ways were investigated in undifferentiated Hfsmc cells 
treated with T for 15 min, 30 min, 2, 6 and 12 h vs. T0 
(time before stimuli addition); 15 min I treatment was 
used as positive control. T significantly induced a rapid 
and persistent (30 min to 12 h) phosphorylation/activa-
tion of AKT, ERK1/2 and mTOR signaling transduction 
pathways (P < 0.05 or P < 0.01 vs. T0) while a tran-
sient (30 min) phosphorylation/inactivation of GSK3β 
(P < 0.05 vs. T0) (Fig. 3a–d). No effects were described 
on GLUT4 protein expression levels (Fig. 3e).
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Fig. 1  Effect of testosterone on Glut4 mRNA expression. Glut1, 
Glut3 and Glut4 mRNA expression was evaluated in undifferenti-
ated or differentiated Hfsmc treated for 24 h with T (100 nM) or I 
(100 nM) for comparison. I or T treatment significantly increased 
Glut4 mRNA vs. control (c) (*P < 0.05; **P < 0.01); no difference 
was observed in Glut subtype 1 and 3 mRNA expression. Results 
(mean ± SE) are derived from three experiments with different cell 
preparations and expressed as fold increase vs. ctr, taken as 1
J Endocrinol Invest 
1 3
Bicalutamide counteracts testosterone effects 
on GLUT4 trafficking and insulin‑related pathway 
activation
The role of AR on T-related GLUT4 trafficking and sign-
aling was investigated in 1 h pre-treated Hfsmc cells with 
the AR antagonist bicalutamide (Bic, 100 nM) then treated 
with T (100 nM) for 30; 15 min I treatment was used as 
positive control.
Immunofluorescence for GLUT4 revealed that Bic pre-
treatment counteracted the GLUT4 signal immunodeco-
ration induced by T (Fig. 4a, upper panels). Furthermore, 
AR antagonism by Bic reduced GLUT4 signal basal 
levels (Fig. 4a, upper panels). Middle and lower panels 
(Fig. 4a) depict, respectively, nuclei DAPI labeling and 
GLUT4/DAPI fluorescence merging for each condition. 
Percentage analysis of GLUT4 positive cells shows that 
Bic pre-treatment significantly counteracted T-medi-
ated GLUT4 translocation by 81.82% ± 2.4 (Fig. 4b, 
P < 0.001 Bic + T vs. T).
Western blot (Fig. 5) showed that Bic pre-treatment sig-
nificantly counteracted T-related phosphorylation/activa-
tion of AKT, ERK1/2, mTOR and GSK3β signaling trans-
duction pathways (P < 0.05 or P < 0.001 vs. T) (Fig. 5a–d).
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Fig. 2  Effect of testosterone on GLUT4 translocation in Hfsmc, 
before and after differentiation. Immunofluorescence analysis (a) 
revealed no signal for GLUT4 membrane expression in control (ctr) 
untreated undifferentiated or differentiated Hfsmc; positive staining 
for GLUT4 was observed after 30-min incubation with I (100 nM) 
or T (100 nM) both in undifferentiated or differentiated conditions 
(upper panels). Cells were incubated with antibody probes specific 
for GLUT4, followed by incubations with fluorescent secondary anti-
body. Middle panels represent DAPI blue staining of nuclei; lower 
panels depict GLUT4/DAPI staining merge. Pictures are representa-
tive. Results are derived from four separate experiments, using dis-
tinct cell preparations. Percentage of GLUT4 positive undifferen-
tiated or differentiated cells (**P < 0.01 vs. ctr) are represented in 
panels of figure b, respectively. Data are expressed as mean ± SE
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Fig. 3  Effect of testosterone on I-related metabolic pathways. The 
treatment of Hfsmc for 15 min with T (100 nM) did not activate any 
of the tested intracellular paths, at variance with I (100 nM), used 
as positive control, (a–d); however, T after 30 min significantly 
induced activation of phospho (p)-AKT, ERK1/2, mTOR and GSK3β 
(*P < 0.05 or **P < 0.01 vs. T0), as depicted by the densitometric 
analysis, reported below each representative blot. Specific total pro-
teins were used as loading controls. Results of densitometric analysis 
(mean ± SE) are expressed as ratio p-/total-protein, fold increase vs. 
T0, taken as 1; data derived from three/four experiments using dif-
ferent cell preparations. Protein analysis revealed no time-dependent 
changes of GLUT4 expression (e)
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Fig. 4  Effect of bicalutamide pre-treatment on testosterone-induced 
GLUT4 translocation in Hfsmc. Immunofluorescence analysis (a) 
revealed no signal for GLUT4 membrane expression in control (ctr) 
untreated Hfsmc; positive staining for GLUT4 was observed after 
30-min incubation with I (100 nM) or T (100 nM) (upper panels). 1-h 
pre-treatment with Bic 100 nM completely counteracted T-induced 
GLUT4 translocation. Cells were incubated with antibody probes 
specific for GLUT4, followed by incubations with fluorescent sec-
ondary antibody. Middle panels represent DAPI blue staining of 
nuclei; lower panels depict GLUT4/DAPI staining merge. Pictures 
are representative. Results are derived from four separate experi-
ments, using distinct cell preparations. Percentage of GLUT4 positive 
cells (*P < 0.05, ***P < 0.001 vs. ctr and $$$P < 0.001 vs. T) are rep-
resented in b. Data are expressed as mean ± SE
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Discussion
Herein for the first time we showed that T exerts an I-like 
effect in human skeletal muscle cells, promoting GLUT4 
translocation and activating I-dependent signal transduc-
tion pathway.
Skeletal muscle system, essential for the postural 
retention and locomotion has been shown to be an active 
organ able to dynamically respond to several molecules 
involved in the regulation of body metabolism, physi-
ologic or pathologic processes, such as T and I, among 
other factors [5–7, 20, 21]. I, targeting muscle, govern 
carbohydrate, lipid and protein metabolism [22], while 
T seemed to mainly affect the body composition [23]. 
Despite T and I have distinct functions, several evidences 
suggest their potential interplay both in physiological and 
in pathological conditions. T-increased levels by physi-
cal activity have been shown to play a key role in skel-
etal muscle tissue homeostasis, metabolism and recovery 
from exercise-induced stress [9–11, 23]. T lower levels 
in men affected by hypogonadism and higher in women 
with polycystic ovary syndrome have been related with 
an increased risk of metabolic syndrome and diabetes 
[24–27]. Inversely, type 2 diabetes is frequently associ-
ated to reduced T levels [28]. In line with our in vitro 
results, T has been shown in humans to exert beneficial 
effects on non-alcoholic fatty liver disease-related insulin 
resistance, indicating a direct insulin-like effect of testos-
terone in skeletal muscle cells [29].
Thus, T, for many years considered the “male hor-
mone” with a “muscular hypertrophying function” seems 
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Fig. 5  Effect of bicalutamide on Testosterone-induced I-related 
metabolic pathways. The pre-treatment with bicalutamide (100 nM, 
Bic) prevented T-induced phosphorylation (p) of AKT, ERK1/2, 
mTOR and GSK3β (*P < 0.05, **P < 0.01 or ***P < 0.001 vs. T0), 
as depicted by the densitometric analysis, reported below each repre-
sentative blot. Specific total proteins were used as loading controls. 
Results of densitometric analysis (mean ± SE) are expressed as ratio 
p-/total-protein, fold increase vs. T0, taken as 1; data derived from 
three/four experiments using different cell preparations
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to influence glucose metabolism independently by gender. 
Starting from these evidences, we documented for the first 
time in human skeletal muscle cells that T, similarly to I, 
shortly activates the intracellular machinery committed to 
metabolic glucose control.
GLUT4 mediates glucose uptake in adipose tissues and 
striated muscle. After binding to receptor, I induces the 
rapid (minutes) translocation of GLUT4 to the cell surface 
that promotes glucose uptake [30] and induces later (hours) 
effects on Glut4 mRNA expression [31, 32]. Recently, 
it has been shown that high-dose testosterone promotes 
GLUT4 translocation and dependent glucose uptake in 
3T3-L1 adipocytes cells [9] while no data have been yet 
collected on human muscle cells. Herein, our results show 
that in non-permeabilized human skeletal muscle cells, 
independently from the differentiation status, 30 min of T 
treatment induced an intense signal specific for GLUT4 
protein, virtually absent in control non-treated cells, when 
GLUT4 is reported to be masked within storage compart-
ments [33], comparable to which described after I treat-
ment. Furthermore, we show that 24 h of T treatment up-
regulate Glut4 mRNA expression without affecting Glut1 
and Glut3 mRNA levels. To date, 14 glucose transporters 
isoforms with a specific pattern of tissue expression have 
been identified [34]. Whether GLUT4 has been found spe-
cifically expressed in adipose tissues and striated muscle 
(skeletal muscle and cardiac muscle), GLUT1 and GLUT3 
result, respectively, expressed in erythrocytes [35] or 
endothelial cells of barrier tissues [36] and in neurons or in 
the placenta [37]. Our results document the ability of T to 
regulate, as I, the expression and trafficking of GLUT4 iso-
form implied in skeletal muscle glucose metabolism.
Following binding to receptor, I activates several signal 
transduction pathways essential for the GLUT4 recruit-
ment and the regulation of several cell functions, pertinent 
to metabolic or proliferative effects [38]. Principally, I acti-
vates the p21ras/MAP kinase (MAPK) (RAS)/extracellu-
lar-signal-regulated kinase (ERK) and the Phosphoinositide 
3-kinase (PI3 K)/AKT pathways known to play different 
role in I-mediated effects. Particularly, whether MAPK/
ERK signaling controls cellular proliferation or differentia-
tion, PI3K/AKT influences GLUT4 trafficking and glucose 
uptake through the phosphorylation-activation of mTOR 
and -inhibition of GSK3β [39–42]. By time-course experi-
ments, we showed that T induced an early and persistent 
phosphorylation/activation of PI3K/AKT/mTOR and RAS/
ERK paths that starts from 30 min, 15 min later than I, and 
lasted up to 12 h as well as a transient phosphorylation/
inhibition of GSK3β. Notably, PI3K/AKT signaling is also 
involved in the regulation of GLUT4 protein expression by 
increased biosynthesis, decreased degradation or both [41]. 
Herein, T or I treatment increased Glut4 mRNA, but not 
protein expression. Whether many studies correlate I levels, 
skeletal muscle cells responsiveness and Glut4 mRNA lev-
els [42], no evidences have still been collected on protein 
expression status. Recently Ma et al. showed that the pro-
longed I stimulation down-regulates GLUT4 in 3T3-L1 
adipocytes [43]. Analyzing our data we can suppose that T 
as I increases the GLUT4 protein turnover that is rapidly 
counteracted by an increase in Glut4 gene transcription and 
translation. Thus, we speculate that whether it is possible to 
check up-regulation in mRNA expression no modifications 
can be described on protein expression levels. The molecu-
lar mechanisms by which I and T acutely and chronically 
regulate GLUT4 half-life will be object of future investiga-
tions. All together, the effects herein shown indicate that T 
is able to induce rapid I-like effects in muscles.
The classical mechanism of T action provides that T 
binding the androgen receptors (AR) activates AR increas-
ing its affinity for specific DNA-binding sites thus promot-
ing, through the recruitment of co-activators or co-repres-
sors, gene expression regulation. In addition to the classical 
mechanism, previous studies have determined that andro-
gens can activate cellular signaling pathways independent 
of AR binding to DNA [1–3]. This “non-classical” mech-
anism has been shown to increase the phosphorylation/
activation of the PI3K/AKT and RAS/ERK pathways in 
mouse skeletal and rat cardiac muscle fibers [1–3, 43, 44]. 
Analyzing our data, we can speculate that in human skel-
etal muscle cells T affects glucose metabolism through the 
AR-mediated activation of the classic pathway, responsible 
for Glut4 mRNA expression, and the non-classic pathway 
that activate PI3K/AKT rapidly predispose cells to glucose 
uptake. Whether mRNA up-regulation mirrors this rapid 
effect, belongs to the classic pathway or involves both the 
ways, has to be elucidated.
In conclusion, our in vitro data provide some biomo-
lecular evidences for I-like effects of T in human skel-
etal muscle cells, thus sustaining also the role of this 
hormone in exerting a short-term direct metabolic con-
trol on muscle. Considering the observed rapid physi-
ological increases of T during acute physical exercise, 
the possible presence of both static and dynamic roles of 
T in supporting metabolic muscle homeostasis and func-
tion in resting conditions, during exercise and recovery 
should be considered. In this sense, we can speculate 
that in in vivo the T increases rapidly during physical 
exercise, also throughout its I-like rapid and prolonged 
effects, that are essential to control skeletal muscle cell 
function and metabolic homeostasis, particularly during 
prolonged exercise and/or during recovery. Consequently, 
further studies are necessary to investigate if these dif-
ferent I-like effects of T are also confirmed in vivo and 
to verify if during/after exercise they are related to the 
reached maximum T concentration per se (i.e., does it 
exist a critical T concentration?) and/or to the observed 
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rapid serum T concentration variation. Besides both the 
individual responsiveness to T and the role of genetic 
factors in the physiologic hormones adaptation to exer-
cise-related stress [45], the possible relationships in vivo 
between T rapid increases and I-like metabolic pathways 
should be evaluated also in healthy athletes assuming 
supplements [46] and/or abusing with prohibited [47, 48] 
and not prohibited [49–52] drugs influencing endocrine-
metabolic pathways. Moreover, if our data are confirmed 
we could also state that athletes often acutely abuse 
with T also because of the rapid effects on T metabolic 
I-related pathways, in addition to possible rapid effects 
of T on neuromuscular system [53]. In fact, from anecdo-
tal reports, athletes could have a benefit for performance 
by abusing with a single dose of T immediately before or 
during a competition [54].
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